LSAQ $9.01 0%
0365.HK $0.38 -1.3158%
KWBE.L $11.80 -0.3968%
E $28.97 0.2422%
2518.HK $57.00 5.0691%
JHPI $20.53 -0.4085%
ENVIU $8.75 0%
MG $7.03 1.8841%
LAZY $11.08 1.4188%
GLLIR $0.07 -34.5545%
ASEI.L $369.00 0%
2886.HK $1.72 0%
AHHX $8.33 0%
CCRV $18.81 -1.2339%
IJH $241.12 -0.5978%
RMBL $8.96 -0.9403%
B28.SI $0.96 1.6949%
IFRX $4.98 1.6327%
PROAC.PA $0.10 13.0952%
ANDE $37.35 0.1609%
IBP $112.88 -1.445%
QLS $25.09 0%
FTRP $0.84 0%
RUR.L $0.36 -10%
SMFR $0.31 -22.3694%
ALTUV.PA $3.67 1.3812%
U $29.43 -9.3346%
DCRNW $1.27 0%
PTVE $7.46 -0.9296%
MS-PK $23.25 -0.1336%
JMBS $46.45 -0.4498%
GBJP.L $3 223.50 0.5459%
MLAAE.PA $2.30 0%
GEA.PA $88.00 -1.1236%
SDOG $48.58 -0.6341%
US71.L $88.74 -0.1407%
LUB $1.78 0%
UG $9.49 1.9334%
0688.HK $19.60 -2%
8117.HK $0.11 -6.77966%
LAGR.L $10.77 -1.9126%
1069.HK $0.01 0%
DX.L $27.15 0.5556%
0QVG.L $13.10 0%
AIMAW $0.06 21.2%
AKRO $45.41 -0.4167%
0348.HK $0.11 -14.6154%
POSH $17.90 0%
MTG $14.74 -0.5735%
MENV $22.72 0%
SPOL.L $1 223.90 1.2659%
MYO $0.50 -0.56%
SITM $82.00 -0.9183%
2017.HK $0.24 0%
FRHC $80.36 -0.9247%
NECB $12.80 -0.5439%
ONEM $16.47 0%
EDTXU $9.50 0%
EWTX $8.93 -6.1482%
EKSO $1.58 -1.25%
MFDD.PA $170.86 0.5059%
SMTC $18.29 -2.2715%
0K4C.L $32.15 3.8627%
COLI $10.07 0%
8062.HK $0.20 0%
XTL $70.28 -0.4407%
JPN.PA $138.44 0.7789%
EXPE $89.13 -2.2912%
ARBE $2.09 -2.7907%
1829.HK $3.68 0%
0322.HK $13.24 -1.3413%
FPO.L $27.22 -2.7857%
MPLS.L $47.00 9.3023%
SFL $8.74 -1.6329%
FLQE $23.82 -1.00599%
KP2.L $0.70 -3.4483%
1508.HK $0.62 -1.5873%
XDNS.L $1 153.50 1.007%
PMVC-UN $9.74 0%
KRP $15.46 0.079%
EVG $9.74 -1.1168%
CASN4.SA $10.00 0%
VIE.PA $27.71 -0.467%
IRTC $125.93 -2.1979%
POET $4.57 -3.9916%
FLXK.L $30.04 -0.2076%
VERU $1.11 -10.1626%
MFA-PB $17.90 -0.3341%
MLLAB.PA $1.51 0%
JJG $72.01 1.3369%
BRIVW $0.00 0%
8260.HK $0.04 0%
JGLD $14.26 0%
ALLO $6.10 -1.2945%
0846.HK $0.31 3.3333%
SCOM $24.88 0%
ANIP $40.60 -7.6223%
0465.HK $0.24 0%
SBFG3.SA $8.44 -3.0999%
GRES $32.98 -0.4813%
Eng
Логотип
Eng
Лого

Viking Therapeutics, Inc. 0VQA.L

$22.08

-$0.89 (-4.05%)
На 18:02, 12 мая 2023

Ключевые показатели

  • Marketcap

    16108697.00000000

  • week52high

    23.32

  • week52low

    2.15

  • Revenue

  • P/E TTM

    0

  • Beta

    0.76193700

  • EPS

    -0.73300000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    25 июл 2023 г. в 20:00

Описание компании

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек